The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation

Cancer Cell

Volumn 26, Issue 2, 2014, Pages 273-287

  Tremblay, Annie M ^a,b,c   Missiaglia, Edoardo ^d,e   Galli, Giorgio G ^a,b,c   Hettmer, Simone ^a,b,c,i,j   Urcia, Roby ^g   Carrara, Matteo ^m   Judson, Robert N ^g,n   Thway, Khin ^e,f   Nadal, Gema ^g   Selfe, Joanna L ^e   Murray, Graeme ^h   Calogero, Raffaele A ^m   DeBari, Cosimo ^h   Zammit, Peter S ^k   Delorenzi, Mauro ^d,l   Wagers, Amy J ^b,c,i   Shipley, Janet ^e   Wackerhage, Henning ^g   Camargo, Fernando D ^a,b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b Harvard University   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g UNIVERSITY OF ABERDEEN   (United Kingdom)

^h UNIVERSITY OF ABERDEEN   (United Kingdom)

ⁱ HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF LAUSANNE   (Switzerland)

^m UNIVERSITY OF TURIN   (Italy)

ⁿ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MYOCYTE ENHANCER FACTOR 2; MYOD1 PROTEIN; TRANSCRIPTION FACTOR YAP1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CARCINOGENICITY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYONAL RHABDOMYOSARCOMA; GENE DOSAGE; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPERACTIVITY; LATENT PERIOD; MOUSE; NONHUMAN; ONCOGENE; PENETRANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SATELLITE CELL; TRANSCRIPTION REGULATION; TUMOR GENE; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

MUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MUSCLE NEOPLASMS; MUSCLE, SKELETAL; MYOD PROTEIN; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; ONCOGENES; PHOSPHOPROTEINS; RHABDOMYOSARCOMA, EMBRYONAL; SATELLITE CELLS, SKELETAL MUSCLE; TRANSCRIPTION FACTORS;

EID: 84905716960     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.05.029     Document Type: Article

References (49)

1. Al-Tahan A., Sarkis O., Harajly M., Baghdadi O.K., Zibara K., Boulos F., Dighe D., Kregel S., Bazarbachi A., El-Sabban M., et al. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma. Pediatr. Blood Cancer 2012, 58:877-884.
2. Barry E.R., Morikawa T., Butler B.L., Shrestha K., de la Rosa R., Yan K.S., Fuchs C.S., Magness S.T., Smits R., Ogino S., et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 2013, 493:106-110.
3. Beauchamp J.R., Heslop L., Yu D.S., Tajbakhsh S., Kelly R.G., Wernig A., Buckingham M.E., Partridge T.A., Zammit P.S. Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells. J.Cell Biol. 2000, 151:1221-1234.
4. Belyea B., Kephart J.G., Blum J., Kirsch D.G., Linardic C.M. Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Sarcoma 2012, 2012:406239.
5. Beyer T.A., Weiss A., Khomchuk Y., Huang K., Ogunjimi A.A., Varelas X., Wrana J.L. Switch enhancers interpret TGF-β and Hippo signaling to control cell fate in human embryonic stem cells. Cell Reports 2013, 5:1611-1624.
6. Camargo F.D., Gokhale S., Johnnidis J.B., Fu D., Bell G.W., Jaenisch R., Brummelkamp T.R. YAP1 increases organ size and expands undifferentiated progenitor cells. Current biology: CB 2007, 17:2054-2060.
7. Chamberlain J.S., Metzger J., Reyes M., Townsend D., Faulkner J.A. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2007, 21:2195-2204.
8. Cornelison D.D., Wold B.J. Single-cell analysis of regulatory gene expression in quiescent and activated mouse skeletal muscle satellite cells. Dev. Biol. 1997, 191:270-283.
9. Creemers E.E., Sutherland L.B., McAnally J., Richardson J.A., Olson E.N. Myocardin is a direct transcriptional target of Mef2, Tead and Foxo proteins during cardiovascular development. Development 2006, 133:4245-4256.
10. Crose L.E., Galindo K.A., Kephart J.G., Chen C., Fitamant J., Bardeesy N., Bentley R.C., Galindo R.L., Chi J.T., Linardic C.M. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. J.Clin. Invest. 2014, 124:285-296.
11. Davicioni E., Anderson M.J., Finckenstein F.G., Lynch J.C., Qualman S.J., Shimada H., Schofield D.E., Buckley J.D., Meyer W.H., Sorensen P.H., Triche T.J. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am. J. Pathol. 2009, 174:550-564.
12. Dong J., Feldmann G., Huang J., Wu S., Zhang N., Comerford S.A., Gayyed M.F., Anders R.A., Maitra A., Pan D. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007, 130:1120-1133.
13. Hatley M.E., Tang W., Garcia M.R., Finkelstein D., Millay D.P., Liu N., Graff J., Galindo R.L., Olson E.N. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell 2012, 22:536-546.
14. Hosur V., Kavirayani A., Riefler J., Carney L.M., Lyons B., Gott B., Cox G.A., Shultz L.D. Dystrophin and dysferlin double mutant mice: a novel model for rhabdomyosarcoma. Cancer Genet 2012, 205:232-241.
15. Jang H., Choi D.E., Kim H., Cho E.J., Youn H.D. Cabin1 represses MEF2 transcriptional activity by association with a methyltransferase, SUV39H1. J.Biol. Chem. 2007, 282:11172-11179.
16. Judson R.N., Tremblay A.M., Knopp P., White R.B., Urcia R., De Bari C., Zammit P.S., Camargo F.D., Wackerhage H. The Hippo pathway member Yap plays a key role in influencing fate decisions in muscle satellite cells. J.Cell Sci. 2012, 125:6009-6019.
17. Judson R.N., Gray S.R., Walker C., Carroll A.M., Itzstein C., Lionikas A., Zammit P.S., De Bari C., Wackerhage H. Constitutive expression of Yes-associated protein (Yap) in adult skeletal muscle fibres induces muscle atrophy and myopathy. PLoS ONE 2013, 8:e59622.
18. Kanisicak O., Mendez J.J., Yamamoto S., Yamamoto M., Goldhamer D.J. Progenitors of skeletal muscle satellite cells express the muscle determination gene, MyoD. Dev. Biol. 2009, 332:131-141.
19. Keller C., Arenkiel B.R., Coffin C.M., El-Bardeesy N., DePinho R.A., Capecchi M.R. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 2004, 18:2614-2626.
20. Kuang S., Kuroda K., Le Grand F., Rudnicki M.A. Asymmetric self-renewal and commitment of satellite stem cells in muscle. Cell 2007, 129:999-1010.
21. Lepper C., Fan C.M. Inducible lineage tracing of Pax7-descendant cells reveals embryonic origin of adult satellite cells. Genesis 2010, 48:424-436.
22. Lian I., Kim J., Okazawa H., Zhao J., Zhao B., Yu J., Chinnaiyan A., Israel M.A., Goldstein L.S., Abujarour R., et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev. 2010, 24:1106-1118.
23. Maestro R., Dei Tos A.P., Hamamori Y., Krasnokutsky S., Sartorelli V., Kedes L., Doglioni C., Beach D.H., Hannon G.J. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999, 13:2207-2217.
24. Meadows S.M., Warkman A.S., Salanga M.C., Small E.M., Krieg P.A. The myocardin-related transcription factor, MASTR, cooperates with MyoD to activate skeletal muscle gene expression. Proc. Natl. Acad. Sci. USA 2008, 105:1545-1550.
25. Missiaglia E., Williamson D., Chisholm J., Wirapati P., Pierron G., Petel F., Concordet J.P., Thway K., Oberlin O., Pritchard-Jones K., et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J.Clin. Oncol. 2012, 30:1670-1677.
26. Mokalled M.H., Johnson A.N., Creemers E.E., Olson E.N. MASTR directs MyoD-dependent satellite cell differentiation during skeletal muscle regeneration. Genes Dev. 2012, 26:190-202.
27. Pallafacchina G., François S., Regnault B., Czarny B., Dive V., Cumano A., Montarras D., Buckingham M. An adult tissue-specific stem cell in its niche: a gene profiling analysis of invivo quiescent and activated muscle satellite cells. Stem Cell Res. (Amst.) 2010, 4:77-91.
28. Parham D.M., Ellison D.A. Rhabdomyosarcomas in adults and children: an update. Arch. Pathol. Lab. Med. 2006, 130:1454-1465.
29. Rossi S., Poliani P.L., Cominelli M., Bozzato A., Vescovi R., Monti E., Fanzani A. Caveolin 1 is a marker of poor differentiation in Rhabdomyosarcoma. Eur. J. Cancer 2011, 47:761-772.
30. Rubin B.P., Nishijo K., Chen H.I., Yi X., Schuetze D.P., Pal R., Prajapati S.I., Abraham J., Arenkiel B.R., Chen Q.R., et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell 2011, 19:177-191.
31. Saab R., Spunt S.L., Skapek S.X. Myogenesis and rhabdomyosarcoma the Jekyll and Hyde of skeletal muscle. Curr. Top. Dev. Biol. 2011, 94:197-234.
32. Schlegelmilch K., Mohseni M., Kirak O., Pruszak J., Rodriguez J.R., Zhou D., Kreger B.T., Vasioukhin V., Avruch J., Brummelkamp T.R., Camargo F.D. Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell 2011, 144:782-795.
33. Seale P., Bjork B., Yang W., Kajimura S., Chin S., Kuang S., Scimè A., Devarakonda S., Conroe H.M., Erdjument-Bromage H., et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature 2008, 454:961-967.
34. Sherwood R.I., Christensen J.L., Conboy I.M., Conboy M.J., Rando T.A., Weissman I.L., Wagers A.J. Isolation of adult mouse myogenic progenitors: functional heterogeneity of cells within and engrafting skeletal muscle. Cell 2004, 119:543-554.
35. Soleimani V.D., Yin H., Jahani-Asl A., Ming H., Kockx C.E., van Ijcken W.F., Grosveld F., Rudnicki M.A. Snail regulates MyoD binding-site occupancy to direct enhancer switching and differentiation-specific transcription in myogenesis. Mol. Cell 2012, 47:457-468.
36. Spalding K.L., Bhardwaj R.D., Buchholz B.A., Druid H., Frisén J. Retrospective birth dating of cells in humans. Cell 2005, 122:133-143.
37. Tajbakhsh S., Bober E., Babinet C., Pournin S., Arnold H., Buckingham M. Gene targeting the myf-5 locus with nlacZ reveals expression of this myogenic factor in mature skeletal muscle fibres as well as early embryonic muscle. Dev. Dyn. 1996, 206:291-300.
38. Tiffin N., Williams R.D., Shipley J., Pritchard-Jones K. PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br. J. Cancer 2003, 89:327-332.
39. Tonelli R., McIntyre A., Camerin C., Walters Z.S., Di Leo K., Selfe J., Purgato S., Missiaglia E., Tortori A., Renshaw, et al. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Clin. Cancer Res. 2012, 18:796-807.
40. Tremblay A.M., Camargo F.D. Hippo signaling in mammalian stem cells. Semin. Cell Dev. Biol. 2012, 23:818-826.
41. Wachtel M., Runge T., Leuschner I., Stegmaier S., Koscielniak E., Treuner J., Odermatt B., Behnke S., Niggli F.K., Schafer B.W. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J.Clin. Oncol. 2006, 24:816-822.
42. Watt K.I., Judson R., Medlow P., Reid K., Kurth T.B., Burniston J.G., Ratkevicius A., De Bari C., Wackerhage H. Yap is a novel regulator of C2C12 myogenesis. Biochem. Biophys. Res. Commun. 2010, 393:619-624.
43. Williamson D., Missiaglia E., de Reyniès A., Pierron G., Thuille B., Palenzuela G., Thway K., Orbach D., Laé M., Fréneaux P., et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J.Clin. Oncol. 2010, 28:2151-2158.
44. Yang Z., MacQuarrie K.L., Analau E., Tyler A.E., Dilworth F.J., Cao Y., Diede S.J., Tapscott S.J. MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. Genes Dev. 2009, 23:694-707.
45. Yoshida T. MCAT elements and the TEF-1 family of transcription factors in muscle development and disease. Arterioscler. Thromb. Vasc. Biol. 2008, 28:8-17.
46. Yu F.X., Guan K.L. The Hippo pathway: regulators and regulations. Genes Dev. 2013, 27:355-371.
47. Zhao B., Wei X., Li W., Udan R.S., Yang Q., Kim J., Xie J., Ikenoue T., Yu J., Li L., et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007, 21:2747-2761.
48. Zhao B., Ye X., Yu J., Li L., Li W., Li S., Yu J., Lin J.D., Wang C.Y., Chinnaiyan A.M., et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008, 22:1962-1971.
49. Zhou D., Zhang Y., Wu H., Barry E., Yin Y., Lawrence E., Dawson D., Willis J.E., Markowitz S.D., Camargo F.D., Avruch J. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc. Natl. Acad. Sci. USA 2011, 108:E1312-E1320.